Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) Insider Sells 5,538 Shares of Stock

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 5,538 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $60.71, for a total value of $336,211.98. Following the sale, the insider owned 15,437 shares of the company’s stock, valued at approximately $937,180.27. The trade was a 26.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Jonathan Zalevsky also recently made the following trade(s):

• On Tuesday, May 19th, Jonathan Zalevsky sold 199 shares of Nektar Therapeutics stock. The stock was sold at an average price of $65.51, for a total value of $13,036.49.

Nektar Therapeutics Stock Up 1.1%

Nektar Therapeutics stock traded up $0.65 during trading hours on Wednesday, reaching $60.92. 676,635 shares of the company’s stock were exchanged, compared to its average volume of 885,212. The firm’s 50 day simple moving average is $73.67 and its 200 day simple moving average is $62.18. The firm has a market capitalization of $2.06 billion, a PE ratio of -7.24 and a beta of 1.13. Nektar Therapeutics has a twelve month low of $8.27 and a twelve month high of $109.00.

Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.82) EPS for the quarter, missing the consensus estimate of ($1.58) by ($0.24). The firm had revenue of $10.86 million during the quarter, compared to analyst estimates of $10.69 million. Nektar Therapeutics had a negative net margin of 284.18% and a negative return on equity of 85.40%. Analysts anticipate that Nektar Therapeutics will post -9.45 EPS for the current year.

Hedge Funds Weigh In On Nektar Therapeutics

Several large investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets lifted its position in Nektar Therapeutics by 93.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 210 shares in the last quarter. KBC Group NV bought a new position in shares of Nektar Therapeutics during the 1st quarter worth approximately $52,000. Deutsche Bank AG boosted its stake in shares of Nektar Therapeutics by 0.8% in the 4th quarter. Deutsche Bank AG now owns 90,743 shares of the biopharmaceutical company’s stock worth $3,837,000 after buying an additional 743 shares during the last quarter. Bayforest Capital Ltd boosted its stake in shares of Nektar Therapeutics by 51.3% in the 4th quarter. Bayforest Capital Ltd now owns 2,541 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 862 shares during the last quarter. Finally, State of Wyoming purchased a new position in shares of Nektar Therapeutics in the 1st quarter worth approximately $67,000. Institutional investors own 75.88% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on NKTR. Wall Street Zen upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, May 17th. Jefferies Financial Group restated a “buy” rating on shares of Nektar Therapeutics in a research note on Wednesday, April 22nd. B. Riley Financial restated a “buy” rating and issued a $150.00 target price (up from $105.00) on shares of Nektar Therapeutics in a research note on Monday, February 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Nektar Therapeutics in a research note on Tuesday, June 2nd. Finally, BTIG Research raised their target price on Nektar Therapeutics from $151.00 to $178.00 and gave the company a “buy” rating in a research note on Monday, April 20th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $149.63.

About Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.